Therapeutic Response

HER2-positive and PD-L1 (CPS) >= 1 status confers therapeutic sensitivity to Carboplatin in combination with Fluorouracil, Pembrolizumab, and Trastuzumab in patients with Adenocarcinoma of the Gastroesophageal Junction.

Statements

Source and description

Keytruda (pembrolizumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized pembrolizumab in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastro-esophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.